Nanotechnological approaches in Ophthalmic delivery systems

International Journal of Drug Development and Research

Volumn 3, Issue 4, 2011, Pages 9-19

  Harikumar, S L ^a   Sonia, Arora ^b  

^a INSTITUTE OF NANO SCIENCE AND TECHNOLOGY   (India)

^b Rayat Institute of Pharmacy   (India)

Author keywords

Dendrimers; Nanosuspensions; Nanotechnology; Ocular Drug delivery; Ocular nanoparticles; Ophthalmology

Indexed keywords

ACICLOVIR; DENDRIMER; EUDRAGIT RS; INDOMETACIN; METHYLPREDNISOLONE ACETATE; METIPRANOLOL; NANOCRYSTAL; NANOPARTICLE; PIROXICAM;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUTION; HUMAN; NANOMEDICINE; NANOTECHNOLOGY; OPHTHALMIC DRUG DELIVERY SYSTEM; OPTICAL TWEEZERS; REVIEW; SCANNING ELECTRON MICROSCOPY; SCANNING PROBE MICROSCOPY; SUSPENSION; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84861319171     PISSN: None     EISSN: 09759344     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Kayser O, Lemke A, Hernandez-Trejo N. The impact of nano-biotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol2005; 6:3-5.
2. Sahoo SK, Labestwar V. Nanotech approaches to drug delivery and imaging. Drug discovery today2003; 8: 1112-1120.
3. Vasir IK, Lahestwar U. Targetted Drug delivery in Cancer therapy, technol. Cancer Res. Treat 2005; 4: 363-374.
4. Boularis HZ Gukayson, Goulet L Loo Xiang C, Kiridrikaova T. Ocular disposition Pharmacokinetics, efficacy and safety of nanoparticle formulated opthalamic drugs. Current Drug 2007; 8:9-18.
5. Lang JC. Ocular Drug Delivery Conventional Ocular Formulation. Adv. Drug Deliv Rev1995; 16:39-43.
6. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular system an overview. Int J Pharm 2004; 269:1-14.
7. Romanelli L, Valeri P, Morrone LA, Pimpinella, Graziani G, Tita B. Ocular absorption and distribution of bendazac after topical administration to rabbits with different vehicles. Life Sci 1994; 54:877-85.
8. Bourlais C, Acar, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic Drug Delivery systems-recent advances. Prog Retin Eye Res1998;17:33-58.
9. Loftssona T, Jarvinen T. Cyclodextrins in Ophthalmic Drug Delivery. Adv. Drug Deliv. Rev. 1999; 36:59-79.
10. Marioides RM, Silva LP. Drug Delivery system; Past, Present and Future. Curr Drug Tar. 2004; 5: 449-55.
11. Webb PA, Orr C. Analytical Methods in Fine Particle Technology, Micromeritics Instrument Corp. Norcros. Stud in Surf Sci and Catal1997; 273-280.
12. Pignatello R Ricupero P, Bucolo C, Maugeri F, Maltese F, Puglisi G. Preparation and characterization of Eudragit Retard nanosuspensions for the Ocular Delivery of Cloricromene. AAPS Pharm Sci Tech 2006; 7: 192-198.
13. Calvo P, Remunan-Lopez C, Vila-Jato JL, Alonso MJ. Chitosan and chitosan/ethylene oxide propylene oxide block copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines. Pharm Res 1997; 14: 1431-1436.
14. Fresta M, Panico AM, Bucolo C, Giannavola, Puglisi G. Characterization and in-vivo Ocular Absorption of Liposome Encapsulated Acyclovir. Journ Pharm and Pharmacol 1999; 51:565-576.
15. Giannavola C, Bueolo C, Maltese A, Vandelli MA, Puglisi G, Lee, M. Fresta VHL. Influence of Preparation Conditions on Acyclovir-loaded Poly-DL-lactic acid Nanospheres and Effect of PEG coating on Ocular Drug Bioavailability. Pharm Res 1999; 20:584-590.
16. López-León T, Carvalho ELS, Seijo B, Ortega-Vinuesa JL, Bastos-Gonzále D. Physicochemical Characterization of Chitosan Nanoparticles: Electrokinetic and Stability Behavior. Jour Colloid Inter Sci2005; 283; 344-351.
17. Bucolo C, Maltese A, Puglisi G, Pignatello R. Enhanced Ocular Anti-inflammatory activity of Ibuprofen carried by a Eudragit RS100 nanoparticle suspension. Ophthalamic Res. 2002; 34:319-323.
18. K. Adibkia, M.R. Siahi Shadbad, A Nokhodchi, A Javadzedeh, M Barzegar-Jalali, J. Barar, G Mohammadi, Y, Omidi. Piroxicam Nanoparticles for Ocular Delivery: physicochemical characterization and implementation in endotoxin-induced uveitis. J. Drug Target 2007; 6:407-416.
19. VHK Li, Wood RW, Kreuter J, Harmia T, Robinson JR. Ocular drug delivery of Progesterone using Nanoparticles. J. Micro-encapsul1998; 7: 3213-3218.
20. Losa C, Marchal-Heussler L, Orallo F, Vila Jato JL, Alonso MJ. Design of New Formulations for Topical Ocular Administration: Polymeric nanocapsules containing metipranolol. Pharm. Res. 1993; 10: 80-87.
21. Marchal-Heussle L, Husaainer J. Value of the new drug carriers in ophthalmology: liposomes and nanoparticles. Eur. J. pharmacol 1990; 13:575-582.
22. Keck CM, Müller RH. Drug nano-crystals of poorly soluble drugs produced by high pressure homogenisation. Europ Jour Pharmacol 2006; 62:3-1.
23. Trotta M, Gallorate M. Patareeno F, Morcel S. Emulsion containing Partially Water-Imisscible Solvent for the Preperation of Drug Nano-Suspensions. Jour Control Relea2001;76:119-28.
24. Merisko-Liversidge E, Liversidge GG, Cooper. Nanosizing: A Formulation approach for Poorly-Water-Soluble Compound. European Jour Pharm. Scienc 2003; 18: 113-120.
25. Van Erdenbrugh B, Froyen L, Vanden Hotter G. Drying of Crystalline drug nano-suspensions the importance of hydrophobicity on dissolution behaviour upon redispersion. Europ Jour Pharm Sci, 2008; 35:127-35.
26. Pignatello R. Eudragit RS 100 Nanosuspension for the Opthalamic Controlled Delivery of Ibuprofen. Europ Jour Pharm Sci 2002; 16:53-61.
27. Sting GL, Ing GB Van Deltlen RG, Younge BR Leavitt JA caused by topical application of Keterolac Opthalamology. Europ journ pharm Sciences 1996; 103:890-898.
28. Sukari E, Flora D. The effect of Particle Size of Polymeric Nanospheres on Intraviteral Kinetics. Opthalomol Resear 2001; 33:31-36.
29. Bourgies J, Alanso M. Ocular Drug Delivery Targeting to Retina and Retinal Pigments epithelium using Polylactide Nanoparticles. Invest. Ophthalmol Vis. Sci. 2003; 440:3562-3569.
30. V. H Li, Patton F, Ocular Drug Delivery of Progesterone using Nanoparticles. J Microencapsul. 1986; 3:213-218.
31. Irache, Ahemad JM J. Albumin Nanoparticles for the Intravitreal Delivery of Anticytomegaloviral drugs. Mini. Rev. Med. Chem. 2005; 5:293-305.
32. Calvo P, Vila-Jato JL. Evaluation of cationic polymer-coated nanocapsules as oculardrug carriers. Int.J. Pharm.1997; 153:41-50.
33. De Campos, Alanso MJ, Campos L. The effect of a PEG versus a Chitosan coating on the interaction of Drug Colloidal Carriers with the Ocular Mucosa. Eur. J. Pharm. Sci.2003; 20:73-81.
34. Quintana A, Wang S low. Folate Design and function of a Dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 2002; 19: 1310-1316.
35. Patton TF, Robinson JR. Ocular Evaluation of Polyvinyl alchol vechile in rabbits. J. pharm. Sci.1975; 64:1312-1316.
36. Milhe, OM Myles C, Junji Yamakawa, Masaya Kawase. Polyamidoamine Starburst dendrimers as solubility enhancers. Int. J. Pharm 2000; 197:239-241.
37. Loftsson, Már Másson T, Tommi Jarvein. Cyclodextrins in drug delivery, Exp. Opin. Drug Deliv. 2005; 2:335-351.
38. Freedman, JohnW. Klein KA, Craig Crosson E. Beta-Cyclodextrins enhances bioavailability of pilocarpine. Curr. Eye Res 1993; 12:641-647.
39. Masterell F, Mura P, Alanso MJ. Formulation and Characterization of triclosan sub Micron emulsions and Nanocapsules, J. Microencapsulation 2004; 216:16-25.
40. Wang X, Dia J, Chen Z. Bioavilability and Pharmacokinetics of Cyclosporin A Loaded pH sensitive nanoparticles for oral administration. J. Controlled release 2004; 97:421.